ByJim
Bloom Posted on December 14, 2018
December 17, 2018 -- InvestorsHub NewsWire -- via NextBigTicker.com -- Shares
of Kali
Inc (OTCMKTS:KALY) have
bounced back to a one-year high, on the company delivering a string
of groundbreaking catalysts. Renewed investor interest in the
stock comes on the announcement of a $300,000 contract for the
production of Hemp-Derived CBD extract for Puration
Inc (OTCMKTS:
PURA).
KALI PRICE ANALYSIS
Kali is also the center of attention, in the cannabis sector, on
announcing a new cannabis pharmaceutical and concentrates business
plan. The acquisition of NCM Biotech a developer and owner of
patented cannabis extraction process also appears to have
strengthened investor confidence in the stock.
After an extended period of consolidation below the $0.01 mark,
Kali has skyrocketed to one-year highs above the $0.01 mark.
Price action activity indicates that the stock could continue
powering high given the strength of the upward momentum.
The stock faces immediate resistance at the $0.02 mark as part
of the emerging uptrend. A breach of the critical resistance
level could open the door for the stock to rally to two-year
highs. The stock looks set to finish the year on a high,
taking into consideration recent developments that affirm growth
prospects.
WHAT DOES KALI DO?
Kali designs, markets and distributes apparel under the VLOV
band. However, in the recent past, the company has expanded its
footprint into the cannabis sector. The company is now
entirely focused on leveraging Cannabis on research and development
all in the effort of coming up with pharmaceuticals for treating
various illnesses and chronic pain.
WHY IS KALI SKYROCKETING
Kali is skyrocketing in the market on announcing a $300,000
contract from Puration. The contract is for the production of
custom hemp-derived CBD extracts. The contract comes just days
after the company completed the acquisitions of a patented cannabis
extraction process.
“With the legalization of hemp farming on the near horizon
as drafted into the pending 2018 Farm Act, the floodgates are about
to open for Kali-Extracts. I am already receiving daily inquiries
to formulate custom hemp-derived CBD extractions,” saidFrederick Ferri, the founder
of NCM Biotech.
The $300,000 hemp contract builds on a long-running partnership
between Kali and Puration. In addition to the partnership, the two
companies in collaboration with other partners have formed a joint
venture dubbed U.S Cannabis Health. The joint venture is for
the production of cannabis extracts for pharmaceutical
applications. The Joint Venture has already signed its first
agreement.
CBD PRODUCT LINE
In pursuit of revenue opportunities in the burgeoning cannabis
sector, Kali has continued to strengthen its product line. The
company is fresh from launching a new line of hemp-derived CBD
infused candies and vapes under the brand name Hemp4mula.
The company is on course to receive a wholesale order upon
completing the production of the Hemp4mula gum. Plans are
also underway to commence the production of hemp-derived CBD
infused mints and gums upon hemp4mula gum production.
NCM BIOTECH ACQUISITION
Product line expansion comes on the heels of Kali signing letter
of intent for the acquisition of NCM Biotech. With the
acquisition, the company is poised to gain access to a vital
patented cannabis extraction process. The extraction process in
question has already been engaged in a number of medical and
pharmaceutical research and development projects.
Kali intends to pursue pharmaceutical and other commercial
applications with the patented extraction process.
“I have received doctor feedback from more than one of our
research initiatives that extracts coming from NCM Biotech’s
patented process are superior in purity and quality to any other
available cannabis extracts,” Mr. Ferri in a statement.
Kali is also the subject of renewed investor interest on
announcing a new business plan. According to the Chief Executive
Officer, focus now shifts towards the development of
pharmaceuticals to treat various illnesses diseases as well as
chronic pain.
The diversified company also intends to concentrate on the
development of health and wellness therapies. The new business plan
seeks to enhance the company’s pursuit of market share in the
cannabis pharmaceutical market poised to reach $50 billion by
2029.
BOTTOM LINE
A spike in share price has not come merely on speculation; it
has come on renewed investor interest and growing confidence about
the company’s long-term growth prospects. The signing of a
$300,000 contract with Puration attests to the company’s focus on
opportunities in the cannabis sector.
Strengthened investors sentiments also come on the company
announcing a new business plan that affirms pursuit of
opportunities in the multi-billion cannabis pharmaceutical
industry. The stock has since climbed high through critical
resistance levels. Initial indication is that the stock will
continue to climb high on pullbacks, heading into 2019.
We will be updating our subscribers as soon as we know
more. For the latest updates on KALY, sign up below!
Disclosure: We have no position in KALY and have not been
compensated for this article.
RELATED ITEMS:KALI INC, KALI
INC. (OTCMKTS:KALY), OTCMKTS:KALY
Insider Financial has also recently posted articles on Hemp, Inc.
(HEMP),
and Cannabis Science, Inc. (CBIS)
Reposted by NextBigTicker.com
Hemp (CE) (USOTC:HEMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hemp (CE) (USOTC:HEMP)
Historical Stock Chart
From Apr 2023 to Apr 2024
